Menu Search
Equities

VIVA Biotech Holdings

VB0:BER

VIVA Biotech Holdings

Actions
  • Price (EUR)0.108
  • Today's Change-0.001 / -0.92%
  • Shares traded--
  • 1 Year change-24.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 17:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

VIVA Biotech Holdings is a China-based investment holding company. The Company is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company’s core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The Company operates its businesses mainly in the United States, China, Europe and other regions.

  • Revenue in HKD (TTM)2.17bn
  • Net income in HKD-346.03k
  • Incorporated2008
  • Employees2.04k
  • Location
    VIVA Biotech Holdings735 Ziping RoadZhoupu Town, Pudong New DistrictShanghai 201318ChinaCHN
  • Phone+86 2 160893288
  • Fax+86 2 158243936
  • Websitehttps://www.vivabiotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.